Industry
Medical - Instruments & Supplies
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Loading...
Open
31.22
Mkt cap
3.6B
Volume
1.7M
High
33.78
P/E Ratio
-24.04
52-wk high
33.78
Low
30.55
Div yield
N/A
52-wk low
11.70
Portfolio Pulse from
December 06, 2024 | 1:45 pm
Portfolio Pulse from
December 05, 2024 | 9:45 am
Portfolio Pulse from
December 05, 2024 | 3:15 am
Portfolio Pulse from
December 03, 2024 | 4:15 pm
Portfolio Pulse from
December 02, 2024 | 6:30 pm
Portfolio Pulse from
December 02, 2024 | 12:15 pm
Portfolio Pulse from
November 27, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 9:35 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 11:01 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.